ChemotherapyFDA-approvedFirst-line
Gemcitabine/nab-paclitaxel
How it works
Gemcitabine/nab-paclitaxel is a combination of two chemotherapy drugs: gemcitabine and nab-paclitaxel. It works by interfering with DNA synthesis and cell division, causing cancer cells to die.
Cancer types
Pancreatic Cancer— All patients
Efficacy
In clinical trials, gemcitabine/nab-paclitaxel improved overall survival and response rates in patients with pancreatic cancer, with approximately 35% of patients achieving a partial response.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Combination Therapy for Resectable Pancreatic Cancer Before Surgery | Pancreatic Cancer | phase-2 | — | Source → |
| Comparing Chemotherapy Options for Advanced Pancreatic Cancer | Pancreatic Cancer | meta-analysis | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.